P972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC-1 VERSUS PHYSICIAN’S CHOICE OF THERAPY IN LONG-TERM FOLLOW-UP OF TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN DARATUMUMAB TRIALS

Detalles Bibliográficos
Autores principales: Weisel, K., Chari, A., Usmani, S. Z., Goldschmidt, H., Mateos, M.-V., Qi, K., Londhe, A., Nair, S., Lin, X., Pei, L., Ammann, E., Kobos, R., Smit, J., Parekh, T., Slavcev, M., Moreau, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429307/
http://dx.doi.org/10.1097/01.HS9.0000846756.44372.25

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429307/
http://dx.doi.org/10.1097/01.HS9.0000846756.44372.25

Ejemplares similares